Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Naylor

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry|October 26, 1999
Heterocyclic analogues of L-citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N(delta)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitorS Ulhaq, E C Chinje, M A Naylor, et al.
Bioorganic & Medicinal Chemistry|January 9, 1999
S-2-amino-5-azolylpentanoic acids related to L-ornithine as inhibitors of the isoforms of nitric oxide synthase (NOS)S Ulhaq, E C Chinje, M A Naylor, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT)J C Bremner, J K Bradley, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicityM A Naylor, B M Sutton, J Nolan, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 9, 2005
Faraday tilting of water-immersed granular bedsR J Milburn, M A Naylor, A J Smith, et al.
Journal of Medicinal Chemistry|September 18, 1992
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivativesM A Naylor, M D Threadgill, P Webb, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H miceB M Sutton, N J Reeves, M A Naylor, et al.
Drug Design and Discovery|January 1, 1993
Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitroM A Naylor, M D Threadgill, H D Showalter, et al.
Anti-Cancer Drug Design|December 1, 1993
Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalinesM A Naylor, M A Stephens, J Nolan, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry|October 26, 1999
Heterocyclic analogues of L-citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N(delta)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitorS Ulhaq, E C Chinje, M A Naylor, et al.
Bioorganic & Medicinal Chemistry|January 9, 1999
S-2-amino-5-azolylpentanoic acids related to L-ornithine as inhibitors of the isoforms of nitric oxide synthase (NOS)S Ulhaq, E C Chinje, M A Naylor, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT)J C Bremner, J K Bradley, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicityM A Naylor, B M Sutton, J Nolan, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 9, 2005
Faraday tilting of water-immersed granular bedsR J Milburn, M A Naylor, A J Smith, et al.
Journal of Medicinal Chemistry|September 18, 1992
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivativesM A Naylor, M D Threadgill, P Webb, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H miceB M Sutton, N J Reeves, M A Naylor, et al.
Drug Design and Discovery|January 1, 1993
Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitroM A Naylor, M D Threadgill, H D Showalter, et al.
Anti-Cancer Drug Design|December 1, 1993
Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalinesM A Naylor, M A Stephens, J Nolan, et al.
Pageof 4